Physician profile
Haley Danielle Ubillus
NPI 1649625856
$1,957.40
in general payments reported to CMS, 2019-2025
23 companies · $307 in 2025
The $307 reported for 2025 was more than what 85% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $314 · 2022: $247 · 2023: $327 · 2024: $763 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $448.27 | 2021-2025 | Omnipod |
| Beta Bionics, INC. | $310.59 | 2024 | Ilet Bionic Pancreas |
| Medtronic, INC. | $301.98 | 2024-2025 | Minimed 780g |
| Dexcom, INC. | $197.17 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $148.32 | 2022-2025 | Skytrofa |
| Abbvie INC. | $67.70 | 2021-2023 | |
| Rhythm Pharmaceuticals, INC. | $52.49 | 2022-2024 | Imcivree |
| Tandem Diabetes Care, INC. | $51.63 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $46.86 | 2021-2024 | |
| Tolmar, INC. | $36.20 | 2023-2024 | |
| Lifescan, INC. | $33.25 | 2021-2022 | |
| Boston Scientific Corporation | $32.18 | 2022 | |
| Kyowa Kirin, INC. | $28.30 | 2024 | Crysvita |
| Azurity Pharmaceuticals, INC. | $24.66 | 2023 | Triptodur |
| Amphastar Pharmaceuticals, INC. | $24.66 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $23.52 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.81 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $21.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.00 | 2024 | |
| Zealand Pharma US, INC. | $19.56 | 2021 | |
| Endo Pharmaceuticals INC. | $15.93 | 2022 | |
| Ibsa Pharma INC. | $15.48 | 2023 | Tirosint, Licart |
| Abbott Laboratories | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Ubillus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.